Rituximab has become the mainstay of systemic therapy for patients with follicular lymphoma and is associated with an improved outcome at both diagnosis and relapse, either as induction or maintenance therapy. The challenge lies in maximizing the benefit of this drug in a condition characterized by multiple relapses.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
van Oers, M. H. et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J. Clin. Oncol. 28, 2853–2858 (2010).
Marcus, R. et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J. Clin. Oncol. 26, 4579–4586 (2008).
Salles, G. et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 112, 4824–4831 (2008).
Salles, G. et al. Rituximab maintenance for 2 years in patients with untreated high tumour burden follicular lymphoma after response to immunochemotherapy [abstract]. J. Clin. Oncol. 28 (Suppl. 15), 8004 (2010).
Friedberg, J. W. et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J. Clin. Oncol. 27, 1202–1208 (2009).
Johnson, P. W. et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J. Clin. Oncol. 13, 140–147 (1995).
Bachy, E. et al. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival—a study from the Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. 28, 822–829 (2010).
Rohatiner, A. Z. et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J. Clin. Oncol. 25, 2554–2559 (2007).
Pettengell, R. et al. Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy [abstract]. J. Clin. Oncol. 28 (Suppl. 15), 8005 (2010).
Thomson, K. J. et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J. Clin. Oncol. 28, 3695–3700 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S. Montoto declares she has received research support from Genentech. D. Wrench declares no competing interests.
Rights and permissions
About this article
Cite this article
Wrench, D., Montoto, S. Maintenance rituximab for relapsed follicular lymphoma. Nat Rev Clin Oncol 7, 677–678 (2010). https://doi.org/10.1038/nrclinonc.2010.186
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.186
